Healthcare Business

Pfizer Blows It Horn To Doubting Thomases

Pfizer (PFE) met with analysts yesterday and said it was on the road to introducing some blockbuster drugs. Wall St. should hope so. With a sales force reduction of 2,000, generics snapping at its heels, Wal-Mart offering $4 prescriptions, and a Democratic Congress that wants to knock down healthcare costs, Pfizer need some big wins.

Pfizer says that its has six drugs in the pipeline to come out before 2011. But, the company has spent $7 billion on research each year and does not have much to show except a lot of drugs that are losing their patent protection.

Pfizer’s biggest upcoming drug is torcetrapib, a drug to boost HDL, or good cholesterol. The company says that it is confident that the drug will do well, but in some trials it raises blood pressure in patients. So, it fixes on thing and damages another.

Pfizer will have to do better than that. Over that last five years, the S&P is up about 20% and Pfizer is off 35%. That would give most investors high blood pressure without torcetrapib.

Douglas A. McIntyre can be reached at [email protected]. He does not own securities in companies that he writes about.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.